Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034063 (pulmonary edema)
 10,665 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of warfarin treatment on an experimental endocarditis was studied in rabbits. Warfarin had no effect on the induction of a Streptococcus sanguis infection in catheter-induced endocardial vegetations, and the course of this infection was also unaltered. However, warfarin treatment resulted in rapidly progressive bacteremia, probably due to impaired circulation in clearing organs such as the lungs, liver, and spleen. Warfarin also reduced the survival time of the infected rabbits, in which pulmonary edema and extensive lung hemorrhages may have been a contributory factor.
 ...
PMID:Effect of warfarin on the induction and course of experimental endocarditis. 100 98

Results of recent clinical trials have unequivocally established the value of intravenous thrombolytic therapy in enhancing survival after acute myocardial infarction. However, the optimum long-term antithrombolytic strategy for prevention of recurrent cardiac complications after thrombolysis is unknown at the current time. To determine whether aspirin or warfarin best prevents postdischarge recurrent cardiac events (unstable angina, reinfarction, pulmonary edema, or/and death), we analyzed the long-term course of 203 patients at our institution who received intravenous thrombolytic therapy (streptokinase, tissue plasminogen activator, or urokinase) for acute myocardial infarction. Of these, 129 (64%) survived to hospital discharge without revascularization--92 patients (71%) received aspirin (325 mg/day). whereas 37 (29%) received warfarin. The choice of drug was made by the treating physician. By a mean of 2.5 years of follow-up, 34 of 92 patients receiving aspirin (37%) versus 6 or 37 receiving warfarin (16%) (p less than or equal to 0.02) had unstable angina, reinfarction, pulmonary edema, and/or death. No life-threatening hemorrhage occurred in either group. Warfarin appears to be superior to aspirin long term in patients with postlysis myocardial infarction for the prevention of recurrent cardiac complications.
 ...
PMID:Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. 235 11

A 31-year-old female had an ascending aortic conduit with a Bjork-Shiley valve placed for an aortic dissection. A year later she became pregnant and was placed on heparin instead of coumadin therapy. She then developed a distal aortic dissection and was hospitalized for close medical monitoring of fetal status and maturity. At 33 weeks of gestation the aortic valve thrombosed, resulting in pulmonary edema and cardiac arrest. Emergency cesarean section and replacement of the aortic valve and ascending aortic conduit was successful in salvaging mother and child. Both are well at 2 years followup. The case illustrates the hazards of prosthetic valves in pregnant patients and cardiac surgery during pregnancy. These issues are reviewed along with the details leading to successful surgical management.
 ...
PMID:Acute thrombosis of a composite ascending aortic conduit containing a Bjork-Shiley valve during pregnancy: successful emergency cesarean section and operative repair. 372 55

Massive left atrial thrombus (MLAT) developed in a patient with porcine heterograft mitral valve, left atrial dilatation, and atrial fibrillation, despite anticoagulant therapy with warfarin sodium (Coumadin). The thrombus obstructed the mitral valve orifice, leading to acute myocardial infarction, pulmonary edema, and death due to cardiogenic shock.
 ...
PMID:Left atrial thrombus despite anticoagulant therapy in a patient with a mitral valve prosthesis. 739 26

Pregnancy is associated with an increased risk of valve thrombosis, hemorrhagic complications, and offspring complications in patients with metallic prosthetic heart valve (MHV). Warfarin treatment is the best regimen against thromboembolic complications, but its use in the first trimester can result in embryopathy. Low molecular weight heparin (LMWH) does not cross the placenta and has some potential advantages. However, the pharmacokinetics of LMWHs change during pregnancy, and serial monitoring of anti-Xa levels is strongly recommended. Despite this recommendation, LMWH therapy in a fixed dose is still used in pregnant women with MHV without monitoring anti-Xa activity in clinical practice. We present three cases of MHV thrombosis occurring while on therapy with LMWH during pregnancy. One of these patients showed cerebrovascular event, one presented with pulmonary edema, and one underwent reoperation for MHV thrombosis.
...
PMID:The use of low molecular weight heparin during pregnancy in patients with mechanical heart valves carries potential risk for valve thrombosis: a report of three cases. 2536 61